Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Starling Oncology, Inc. (STLN : NSDQ)
 
 • Company Description   
Starling Oncology Inc. is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. Starling Oncology Inc., formerly known as The Oncology Institute Inc., is based in CERRITOS, Calif.

Number of Employees: 641

 
 • Price / Volume Information   
Yesterday's Closing Price: $5.93 Daily Weekly Monthly
20 Day Moving Average: 1,084,515 shares
Shares Outstanding: 98.84 (millions)
Market Capitalization: $586.12 (millions)
Beta: 0.41
52 Week High: $7.05
52 Week Low: $2.32
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -3.73% -3.30%
12 Week 14.48% 12.04%
Year To Date 66.57% 47.73%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
18000 STUDEBAKER ROAD SUITE 800
-
CERRITOS,CA 90703
USA		 ph: 562-735-3226
fax: -		 investors@icrinc.com http://www.starlingoncology.com
 
 • General Corporate Information   
Officers
Daniel Virnich - Chief Executive Officer and Director
Robert Carter - Chief Financial Officer
Karen Johnson - Director
Mohit Kaushal - Director
Mark Stolper - Director

Peer Information
Starling Oncology, Inc. (CORR.)
Starling Oncology, Inc. (RSPI)
Starling Oncology, Inc. (CGXP)
Starling Oncology, Inc. (BGEN)
Starling Oncology, Inc. (GTBP)
Starling Oncology, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 68236X100
SIC: 8011
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/26
Next Expected EPS Date: 11/12/26
Share - Related Items
Shares Outstanding: 98.84
Most Recent Split Date: (:1)
Beta: 0.41
Market Capitalization: $586.12 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.07 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.21 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 11/12/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 1.00
EPS Growth
vs. Year Ago Period: 46.67%
vs. Previous Quarter: -300.00%
Sales Growth
vs. Year Ago Period: 34.62%
vs. Previous Quarter: 9.39%
ROE
06/30/26 - -
03/31/26 - -
12/31/25 - -
ROA
06/30/26 - -21.51
03/31/26 - -24.68
12/31/25 - -33.70
Current Ratio
06/30/26 - 1.36
03/31/26 - 1.47
12/31/25 - 1.59
Quick Ratio
06/30/26 - 1.15
03/31/26 - 1.17
12/31/25 - 1.35
Operating Margin
06/30/26 - -6.18
03/31/26 - -7.42
12/31/25 - -10.93
Net Margin
06/30/26 - -6.18
03/31/26 - -7.42
12/31/25 - -11.45
Pre-Tax Margin
06/30/26 - -6.18
03/31/26 - -8.00
12/31/25 - -12.08
Book Value
06/30/26 - -0.25
03/31/26 - -0.16
12/31/25 - -0.16
Inventory Turnover
06/30/26 - 24.74
03/31/26 - 24.44
12/31/25 - 26.71
Debt-to-Equity
06/30/26 - -
03/31/26 - -
12/31/25 - -
Debt-to-Capital
06/30/26 - -
03/31/26 - -
12/31/25 - -
 

Powered by Zacks Investment Research ©